Category: Today’s Highlights
About the News from Incyte and Vertex
Incyte: A Good Company Facing Irrelevant Investors’ Reaction Incyte decided to stop an early ongoing trial of a combination treatment ruxolitinib (Incyte) plus regorafenib (Bayer) for colon cancer after observing the combination wasn’t working. Both drugs are approved for different...
Read More
January 28, 2016
0
Halozyme: Reading the News While Keeping Our Focus on the Promises
Halozyme Therapeutics (HALO) seems to have closed the previously announced $150 million royalty-backed debt transaction with investment funds managed by Pharmakon Advisors and Athyrium Capital Management. The debt is said to be secured by future royalties of ENHANZE™ products, received...
Read More
January 27, 2016
0
Theravance Biopharma: Launching Vibativ in Canada for MRSA
Theravance Biopharma (TBPH) announced the commercial launch of VIBATIV® (telavancin) in Canada. VIBATIV is a once-daily antibiotic with a dual mechanism of action against Gram-positive bacteria, including difficult-to-treat methicillin-resistant Staphylococcus aureus (MRSA). The drug is approved in Canada for adult...
Read More
January 26, 2016
0
Revolutionary Approaches Towards Managing Chronic and Deadly Diseases
The Market is Surely Ignoring the Historical Summit Biotech achievements are standing on Right Now The latest biotech sector’s breakthroughs we presented was the novel powerful gene editing techniques CRISPR/cas9 an d TALEN. Our article in the Prohost...
Read More
January 22, 2016
0
OIL: A Blessing or a Curse? It Depends on What Some Want it to Be
Escaping the slaughter, or taking advantage of it, or accumulating the stocks we love, or turning from positive to negative investors are all choices on the table. The problem is that the prophets stop prophesizing at times when prophesies are...
Read More
January 20, 2016
0
How Far Can the Market Go in Ignoring Gilead?
On Oct. 28, 2015, Gilead Sciences (GILD) announced that it has submitted a New Drug Application (NDA) to the FDA for an investigational, once-daily fixed-dose combination of the approved nucleotide analog polymerase inhibitor sofosbuvir (Sovaldi®) abbreviated as (SOF) and the...
Read More
January 5, 2016
0
Exelixis Has Good News
Exelixis Announces Positive Results from Subgroup Analyses of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma - The results will be Presented at ASCO 2016 Genitourinary Cancers Symposium this month. - Data further highlight clinical...
Read More
January 5, 2016
0
Steps Forward in the Management of Inflammatory and Autoimmune Diseases
Improving the management of inflammatory and autoimmune diseases has been a dream that seems to be happening slowly but surely in the past years. The improvement has gained energy and speed in 2015. The advancement in treatments has been demonstrated...
Read More
January 8, 2016
0
Of the Biotech Sector Selloff. Spark Presents its Current and Future Programs
Of the Biotech Sector’s Selloff Testing the lows in biotech firms’ stock prices is nothing but testing the biotech investors’ degree of vulnerability to fear. Fear leads many biotech investors to hysterically sell their stocks just by hearing negative stories...
Read More
January 12, 2016
0
News from Incyte and Gossip About Medivation
Incyte (INCY) and Eli Lilly (LLY): Th e New England Journal of Medicine published detailed results of RA-BEACON — a pivotal phase 3 global study of baricitinib , a once-daily oral treatment for moderate-to-severe rheumatoid arthritis (RA). The...
Read More
March 31, 2016
0
Search ProhostBiotech
Popular Links
23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)